Category Archives: Regenerative Medicine

DR. JOEL LOPEZMedical Director, J.Lopez, M.D. Medical Group

Treating the root of the illness, and not the symptoms, is key to enduring healthcare that is his prescriptionA strong and healthy immune system is definitely our bodys first line of defense [against] Covid-19 (coronavirus disease 2019) and other illnesses, declares Dr. Joel Lopez, medical director of the J. Lopez, M.D. Medical Group.

Dr. Lopez was about to start a two-hour webinar (online seminar) for medical professionals and laymen on How to Fortify your Immune System and Vitamin C when Boardroom Watch reached him on April 6.

Holistic treatmentsPending the availability of a safe and effective vaccine for Covid-19, Dr. Lopez recommends nutritional supplements to boost ones immune system. Vitamin C should be given to high-risk individuals, such as frontliners, the elderly and the frail, to help boost [their] innate natural immunity, he says.

American chemist, biochemist and chemical engineer Linus Carl Pauling, a double Nobel laureate for his extensive studies on the benefits of Vitamin C, is Dr. Lopez role model.

There are numerous studies showing that vitamins A, C, D3 and E, as well as minerals such as magnesium, selenium and zinc, can be effective prophylaxis against any type of infection, Dr. Lopez says, adding some wry advice: To cope with stress during the Covid-19 [pandemic], lessen the time watching or listening to news you find upsetting.

Dr. Lopez, who has set up clinics in Alabama, Florida, Indiana, Illinois and California, is now based in the Philippines, caring for his aged mother and giving back to his countrymen. He still maintains his San Francisco office, though. My mom (Dr. Adelina San Juan-Lopez) is a dentist, but most of her siblings are doctors, while several cousins on both sides of the family are medical doctors who practice locally and in the US. Im the only specializing in integrative, biological and regenerative medicine, he says.

Hi dad Tomas, an accountant who sold medical supplies and equipment, passed away two years ago.

NATURES WAY Dr. Lopez (back row, far left) with colleagues during his residency at Mercy Hospital & Medical Center. Below is him sweating it out at the gym. CONTRIBUTED PHOTOS

Back on home ground in 2013, Dr. Lopez opened a clinic at The Medical City on Ortigas Avenue, Pasig City, followed last year by a 28-story outpatient facility in Poblacion, Makati City that deals with integrative, holistic, functional, biological and orthomolecular (right molecules in the right amounts) medicine. His mission statement is to transform, boost, and maintain patients overall wellness.

Filipinos are very receptive to this type of medicine, Dr. Lopez says. Growth can be achieved by educating the public about the basics of nutrition/prevention. He has been practicing holistic medicine for 16 years. To be able to train more medical professionals in this field is his long-term goal.

I prefer that they shadow me while Im seeing clients, Dr. Lopez says. For more theoretical training, I share my textbooks and recommend conferences that I [attended], such as the American Academy of Anti-Aging Medicine, the Institute of Functional Medicine and the Orthomolecular (right molecule) Medicine Group.

Dr. Lopez, who is 54, emphasizes that his biological age is younger, and more important

For optional results, he partners with the client to heal the body, mind, spirit and emotions. He addresses premature aging factors, such as nutritional deficiencies, chronic inflammation, hormonal imbalance, oxidative stress (fatigue, cramps, pain) and poor detoxification mechanisms.

We treat the underlying causes of illness, rather than just treating symptoms. My practice is based on the 7Ps: Personalized, Predictive, Precise, Preventive, Proactive, Partnership and Pharmaceutical grade supplements, he says.

He uses natural remedies (macro and micronutrients, herbals), along with bioidentical (man-made) hormones, peptides, (short strings of amino acids), cell extracts and homeopathy (treatment using natural substances). He applies medication only in an emergency.

Leave it to natureDr. Lopez says integrative medicine allows him to harvest the wisdom of traditional practices and fused with the continued growth of modern science. He also uses a four-step series, called Methodical Dynamics, to furnish a systematic approach to treatments.

Health should be approached holistically since the body and mind are connected, says Dr. Gracielle Consing, The Medical Groups operations manager.

Dr. Daniel J. Dunphy, The Medical Groups visiting practitioner, adds: The good physician cures illness, while the excellent physician prevents it. Harvie Baron, the Medical Groups nutrition coach and food educator, lives by this principle: Transform your health through the healing power of food.

As vice president and founding member of the Preventive Regenerative, Integrative Medical Association since 2014, Dr. Lopez aims to bring optimizing health for a youthful life practice into the mainstream and set up practice standards.

The aging process starts at 30 when our body doesnt produce enough hydrochloric acid to digest food protein, resulting in less less amino acid supplying the brain, he says. One or two teaspoons of apple cider before meals can help the body digest food better. It mimics the effect of hydrochloric acid in the body and is a treatment for indigestion.

Sometimes, you just have to go back to nature to solve nagging health problems and live longer, says Dr. Lopez. Walnuts prevent memory from declining. Fish, especially the small ones like the humble dilis (anchovies), have fatty acids that prevent inflammation. Clean water, air, sleep, exercise, stress reduction, detoxification and nutritional supplements are daily prevention practices.

Because diet influences aging, Dr. Lopez says he eats organic, in-season produce. These contain no hormones that destroy cells. When I wake up in the morning, that means Im still around for a purpose: To glorify Him in all things I do, in my professional and personal life. I read the Bible. He drinks a healthy milkshake for breakfast, as well as nutritional supplements. He exercises at the gym in the late afternoon or early evening. Exercise is one of the best anti-aging tools. It improves the muscle mass and lessens body fat, he says.

Dr. Lopez graduated with a bachelor of science in medical technology in 1986, followed by a doctor of medicine degree in 1990 from Far Eastern University. As a volunteer physician in 1992, he taught holistic healthcare in isolated rural areas in Palawan province, as well as on medical missions in Thailand. He later completed his degree in internal medicine at the University of Illinois at Chicago and his residency at the Mercy Hospital & Medical Center in Chicago.

In 1996, he trained with one of Americas well-known pioneers in alternative medicine, Dr. Gus Prosch. He also taught yoga and chi gong (exercises for cultivating healing energy) on the side.

Dr. Lopez is a very good, compassionate and innovative physician. He is a very dedicated and tireless medical researcher who is always looking for new ways to holistically heal his patients, says Dr. Chiedu J. Nchekwube of Merrillville, Indiana, under whom Dr. Lopez worked directly in 2010.

But perhaps, the best testimonies come from those whom Dr. Lopez has treated. These are recorded on The Medical Groups website.

Joel is not going to throw a bunch of pharmaceuticals at you. He will get to the root cause of why your body is not in balance, and work to adjust it naturally, as much as possible, says Jaye Wittaker, a US-based patient.

Avegay L. from Fremont, California, adds: Dr. Lopez will not just treat the symptom of the disease, but will also treat the root and cause of the problem. I want to age gracefully and to look and feel healthy. Even my boyfriend is now being treated by Dr. Lopez.

He explains all tests so we can understand everything. He takes the time to answer our emails and phone calls when we need advice or help, say Sandi and Fred Herrera, a Filipino couple living in Manila.

Through diagnosis, detoxification, healing and rejuvenation, Dr. Lopez regularly reaches his ultimate goal. And that is to have patients take active control of their health and wellness.

* * *

WHOS AFRAID OF AGING?

Dr. Joel Lopezs individual approach in managing clients nutritional concerns is reflected through four Methodical Dynamics pillars. Your body is a home that you will live in forever, he says. Embrace, love and take care of it. Its the best thing you can ever do for yourself.

Step 1: Early Detection allows us to see what the body needs and how it can be better aided. This describes a 360 degree-approach to your consultation. Strategically designed questions are combined with the test results from the Medical Groups Integrative Innovations. This process allows the physician to find the best approach to the clients current concerns or preventive treatment.

Step 2: System Destress tackles the symptoms and possible causes that prevent the individual from reaching optimal health. It aids in body detoxification to allow the body to best receive the recommended treatments. Our bodies go through so much because of the environment and diets alone. This step in the Methodical Dynamics series helps the body to purify itself for better absorption of nutrients.

Step 3: Restore brings the body into a state of health that allows its very self to maximize its very potentials. Restore allows the body to regain its optimal state. Innovations in the practice of Integrative Medicine are used to allow the body to heal itself naturally.

Step 4: Regenerate stabilizes the foundations of the body with the support needed for the patients goals. Regenerate helps rebuild healthy cells as the person ages. With J. Lopez, M.D. Medical Group, Inc., regeneration supports these building blocks using the recommended nutrients and minerals each individual needs. This approach supports clients ageing process for the long term.

Continue reading here:
Dr. Wellness The Manila Times - The Manila Times

Stryker Corporation and NuVasive

Regenerative Medicine Market: Competitive Landscape

The last chapter of the Regenerative Medicine market research report focuses exclusively on the competitive landscape. It examines the main market players. In addition to a brief overview of the business, analysts provide information on their assessment and development. The list of important products in preparation is also mentioned. The competitive landscape is analyzed by understanding the companies strategies and the initiatives they have taken in recent years to overcome intense competition.

Regenerative Medicine Market: Drivers and Restraints

The report explains the drivers of the future of the Regenerative Medicine market. It assesses the different forces which should have a positive impact on the whole market. Analysts have looked at investments in research and development for products and technologies, which should give players a significant boost. In addition, the researchers undertook an analysis of the evolution of consumer behavior which should have an impact on the cycles of supply and demand in the Regenerative Medicine market. In this research report, changes in per capita income, improvement in the economic situation and emerging trends were examined.

The research report also explains the potential restrictions on the Regenerative Medicine market. The aspects assessed are likely to hamper market growth in the near future. In addition to this assessment, it offers a list of opportunities that could prove lucrative for the entire market. Analysts offer solutions to turn threats and restrictions into successful opportunities in the years to come.

Regenerative Medicine Market: Regional Segmentation

In the following chapters, analysts have examined the regional segments of the Regenerative Medicine market. This gives readers a deeper insight into the global market and allows for a closer look at the elements that could determine its evolution. Countless regional aspects, such as the effects of culture, environment and government policies, which affect regional markets are highlighted.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=7157&utm_source=COD&utm_medium=007

What will the report contain?

Market Dynamics: The report contains important information on influencing factors, market drivers, challenges, opportunities and market trends as part of the market dynamics.

Global Market Forecast: Readers receive production and sales forecasts for the Regenerative Medicine market, production and consumption forecasts for regional markets, production, sales and price forecasts for the Regenerative Medicine market by type and consumption forecasts for the Regenerative Medicine market per application.

Regional Market Analysis: It can be divided into two different sections: one for the analysis of regional production and one for the analysis of regional consumption. Here, analysts share gross margin, prices, sales, production, CAGR, and other factors that indicate the growth of all regional markets examined in the report.

Market Competition: In this section, the report provides information on the situation and trends of competition, including mergers and acquisitions and expansion, the market shares of the three or five main players and the concentration of the market. Readers could also get the production, revenue, and average price shares of manufacturers.

Key Players: The report provides company profiles for a decent number of leading players in the Regenerative Medicine market. It shows your current and future market growth taking into account price, gross margin, income, production, service areas, production locations and other factors.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/global-regenerative-medicine-market/?utm_source=COD&utm_medium=007

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Get Our Trending Report

https://www.marketresearchblogs.com/

Tags: Regenerative Medicine Market Size, Regenerative Medicine Market Trends, Regenerative Medicine Market Forecast, Regenerative Medicine Market Growth, Regenerative Medicine Market Analysis

The rest is here:
Regenerative Medicine Market 2020 Break Down by Top Companies, Applications, Challenges, Opportunities and Forecast 2026 Cole Reports - Cole of Duty

MIAMI, April 16, 2020 /PRNewswire/ -- TissueTech, Inc., the pioneer in the development and clinical application of regenerative human birth tissue products, announced today that the U.S. Food and Drug Administration (FDA) has granted their cryopreserved human umbilical cord investigational biologic product TTAX02 RMAT designation for the treatment of spina bifida in-utero.

This designation aims to streamline development of regenerative medical products used in the FDA's Investigational New Drug (IND) program for the treatment of serious or life-threatening diseases such as spina bifida. In spina bifida, the spinal canal opens along vertebrae in the lower or middle back of the fetus. It is the most common neural tube defect in the U.S. and is characterized by incomplete development of the brain, spinal cord, and/or protective covering around the brain and spinal cord.1

"Although rare, patients who suffer from open spina bifida have a ten times greater death rate than the national average from ages five to 40 years,"2 said Amy Tseng, TissueTech Co-Founder, President and Chief Executive Officer. "This RMAT designation highlights the need for an effective treatment for this life-threatening condition and the great potential TTAX02 holds."

The benefits of in-utero fetal surgery are promising and include less exposure of the vulnerable spinal nerve tissue and bone to the intrauterine environment. Additionally, doctors have discovered that in-utero fetal surgical repair of spina bifida may positively affect fetal hindbrain development in-utero, decreasing the severity of certain complicationssuch as Chiari II and hydrocephalusor reduce the need for surgery to implant a shunt.1

In addition to the RMAT designation, TissueTech is also planning to conduct a Phase 3 clinical trial to demonstrate the safety and efficacy of TTAX02 when used as a single patch to cover the neural placode, or a dual patch to close both the skin and meningeal defects during in-utero fetal surgical repair of spina bifida, to determine if it may improve clinically meaningful neurological outcomes after birth.

About TissueTech, Inc.TissueTech, Inc.,the parent company of Amniox Medical, Inc. and Bio-Tissue, Inc., pioneered the development and clinical application of human birth tissue-based products. Founded in 1997, Bio-Tissue markets products for the ophthalmology and optometry markets; and Amniox markets products for use in the musculoskeletal and wound care markets. Clinicians have performed more than 500,000 human implants with the company's products and published more than 360 peer-reviewed studies supporting its technology platform. The Company's first product, AmnioGraft, is the only tissue graft designated by the FDA as homologous use for promoting ophthalmic wound healing as acting as an anti-scarring, anti-inflammatory and anti-angiogenic agent and supporting epithelial adhesion and differentiation. Learn more at https://tissuetech.com/.

Physicians are encouraged to visit the TissueTech Physician Portalto learn more about TissueTech's platform technology, review product application guides, and view educational webinars.

1 https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Spina-Bifida-Fact-Sheet

2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2786149/

SOURCE TissueTech

tissuetech.com

Here is the original post:
TissueTech Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from US Food and Drug Administration - PRNewswire

What to know

The CDC is recommending that everyone wear a cloth mask when going out in public. The Manufacturing Development Center at the Wake Forest Institute for Regenerative Medicine, part of Wake Forest Baptist, recently conducted tests of about 400 cloth masks made by community volunteers. The tests looked at how well various types of material filtered out particles the size of many viruses and bacteria (0.3-1.0 microns in diameter). The effectiveness of the masks varied widely, with the best reaching 79% filtration compared to surgical masks at 62% to 65% filtration and N95 masks at 97%. However, according to Dr. Scott Segal, the chair of anesthesiology at Wake Forest Baptist and the originator of the tests, the worst-performing masks filtered out only 1% of particles. Here are some of the findings and other recommendations from Segal.

Tight weave fabric that doesnt show much light passing through is a good performing design.

Best materials and designs

Two layers of high-quality, heavyweight quilters cotton with a thread count of 180 or more

Fabrics with an especially tight weave and thicker thread, such as batiks or heavy T-shirt fabric

Double-layer mask with a simple cotton outer layer and an inner layer of flannel

A lower grade cotton (more open weave) with light passing through is a poorer performing design.

Inferior materials and designs

Single-layer masks

Double-layer designs using lower quality, lightweight cotton

Fabric used in breathable T-shirts designed to be porous

How can you tell suitable fabric?

Use the light test: If you hold the fabric up to a bright light, it shouldnt be easy to see light coming through it, and you shouldnt see a lot of light outlining the weave.

Other things to know

Masks are mostly to protect other people by reducing the chance an infected wearer can spread virus droplets by sneezing or coughing, even before they show other symptoms. However, masks can provide some protection for an uninfected wearer, depending on effectiveness.

Segal recommends using a design with ties over elastic loops, because ties can provide a tighter and more customizable fit. It can also be difficult to find elastic, and elastic can break down with repeated washings.

A well-fitting mask is likely to feel a bit uncomfortable and stuffy when wearing it. Wearing a mask takes some getting used to even for medical professionals, Segal said. You could try wearing a mask in your house first to get adjusted to it.

Dont touch your face after positioning the mask, and dont adjust the mask while youre out. This could spread any virus particles that get on the mask.

Its important to be able to breathe through the mask, and very thick fabric or HEPA vacuum bags could make that difficult. If a person cant breathe through the mask, theyre likely either to ditch the mask or to breathe around the sides of it, Segal said, defeating the purpose of wearing a mask.

Some vacuum bags and filter materials contain fiberglass threads, which could be dangerous to inhale.

Some mask designs utilize a pocket for a replaceable filter. The Baptist study didnt find that a filter added much more effectiveness to already good designs, but Segal said that some places have had success with them, so they are an option.

Even if a masks material isnt the best, something is generally better than nothing when it comes to covering your face.

NOTE

Homemade masks are no substitute for staying home, social distancing and proper handwashing technique (at least 20 seconds with soap and water). Those are still the best ways to fight the COVID-19 virus. Dont let wearing a mask give you a false sense of security or entice you to relax your social distancing.

What youll need

Removing and caring for masks

Wash hands after removing the mask and after changing the interior filter, if your mask has one. Change the filter after every time you go out.

Moisture from your breath makes the mask less effective, so dont reuse a wet mask.

Untie by the straps. Dont touch the front of the mask as you remove it.

Wash masks in the washing machine with detergent in hot water after use.

Go here to read the rest:
Face Masks: What to know, and how to sew your own - Winston-Salem Journal

Throughout history, the nations colleges and universities have set the foundation for innovation and social change. Weve uncovered the secrets of DNA. Weve unleashed bioengineering. We have harnessed intellectual power to create new technologyoften through the partnerships between land grant colleges and local industries and agriculturebringing the latest science to where it was needed. And we have done it all while demanding intellectual rigor and a sharp focus on the common good for society.

At Boston University, the Center for Regenerative Medicine at BUs Medical Center, alerted by colleagues at the University of Washington in Seattle, coordinated with MITs Broad Institute as well as Harvard to produce a test for the virus with a turn around time of within 24 hours. More than 50 volunteered in this round the clock effort. Testing is now underway. Rutgers University has launched its own virus testing program. Its RUCDR Infinite Biologicsa part of the Universitys Human Genetics Institute of New Jerseyis now capable of testing tens of thousands.

Tiny Bay Mills Community College, a Michigan tribal college of fewer than 500 students, has used 3-D technology to design and now produce 1,000 face masks for first responders every week.

Institutions of higher education, large and small, can and do play a significant role in serving our country and our world at this critical moment in history. But our work starts at home. Whats required is a community approach, as local areas are impacted in distinct ways while this crisis unfolds.

I learned the power of community response to overwhelming challenges at the American University of Nigeria. I served there as president when Boko Haram began to surge near the campus and federal assistance was nowhere to be found. The university brought the community together and kept the terrorist group at bay and fed refugees.

Drawing on that experience, when I arrived at Dickinson three years ago, I immediately began to gather with community members to identify their most pressing issues and to connect them with college resources. What started out as a dozen people has now grown to more than 50 representing nearly every sectornonprofits, school districts, health care, government and business. We are meeting remotely in the age of COVID-19, but the relationships we have built have allowed us to respond quickly in a coordinated manner to the communitys growing needs.

Working with Carlisle Borough, the Chamber of Commerce and Community CARES partnered to convert the Stuart Community Center into a shelter for the homeless. UPMC Carlisle anticipated a potential need for housing and shelter for its exhausted medical workers; Dickinson stepped up and agreed to make space available in our vacated residence halls. Local businesses needed an online presence to offer goods and services, but lacked the know-how; Dickinson students are developing e-commerce websites for those businesses. Our organic farm is supplying much-needed fresh produce for the community.

Colleges areand should beat the epicenter of community responses to COVID. They can and should be the assembly point for community action. Its imperative that colleges start building or strengthening relationships with leaders in their communities now, to help in recovery and before the next crisis or disaster occurs.

When students return to class, they will return to communities that have changed in myriad ways. The old ideas, approaches and leadership simply wont do. Our students and young people are the ones we will need to help us with the necessary reconstruction. Those students will rely on the knowledge and problem-solving skills our institutions of higher learning should be providing.

In these difficult times, the country must demand much of its colleges and universities. Communities must know that we are in the trenches with you, and that we are all of us prepared to do more. When students return to our campuses we should work together to build a program of national service. This is how we will rebuild America and prepare the next generation for more unprecedented challenges.

Margee M. Ensign is president of Dickinson College, in Carlisle. Previously, Ensign served as president of the American University of Nigeria, where she developed aid and relief programs for hundreds of thousands of internally displaced people fleeing Boko Haram.

Go here to see the original:
Community resilience is facing Its greatest threat, and colleges are helping | Opinion - pennlive.com

Biotech company Mogrify is deploying its proprietary direct cellular conversion technology to develop cell therapies in a variety of disease areas, including auto-immune, musculoskeletal, respiratory diseases and in cancer immunotherapy.The platform utilizes data from next-generation sequencing and cellular networks to identify transcription factors or small molecules required to directly convert a cell, addressing key challenges that are typically associated with the safety and efficacy of cell therapies.Technology Networks recently spoke with Joe Foster, COO, Mogrify, to learn more about the platform, the challenges encountered in developing cell therapies, and to gain Mogrify's insights on the future of this exciting research space.Molly Campbell (MC): What were some of the major highlights for Mogrify in 2019?Joe Foster (JF): In the past year, Mogrify has solidified its reputation as a pioneer in the expanding field of cell therapy. Using a systematic, data-driven approach, our innovative cell conversion platform addresses many of the challenges impeding systematic discovery, process development and the manufacturing processes.At an operational level, Mogrify has seen unprecedented growth in the last year, with emphasis on world-class science. We have established a leadership team with unparalleled track records, including the appointment of Dr Darrin M. Disley OBE, as CEO and Dr Jane Osbourn OBE, as Chair. Looking forward and with plans to boost our team to 70 individuals working across all disciplines, Mogrify has also moved operations to the new Bio-Innovation Centre in Cambridge, giving our team access to state-of-the-art facilities to continue their work in developing novel approaches to cell therapy.Mogrify received MSDs Innovation Award at the 15th Annual Scrip Awards, in acknowledgement of our potential to transform future cell therapies. Dr Jane Osbourn OBE was also the first female to win the Lifetime Achievement Award, recognizing her significant contributions to the biotech industry. Mogrifys significant fundraising success was also marked at the prestigious European Lifestars Awards, which celebrates excellence in the life science industry. Here, Mogrify was recognized as the Seed Stage Finance Raise of the Year.MC: In Mogrify's opinion, what key trends can we expect to see in the cell therapy space in 2020?JF: Many of the current approaches to cell therapy involve first converting cells back into a stem cell-like stateinduced pluripotent stem cellsbefore then converting them into the cell type required.Mogrify plans to lead the movement towards direct cell conversion, or transdifferentiation, where cells can be transformed from one cell type to another, without having to go through an intermediate pluripotent stage. Direct conversion of cells would enhance the speed of cell therapy development, as cells do not need to use traditional developmental pathways to reach a mature state.

Another bottleneck in the delivery of cell therapies is that most approaches rely on autologous transplants, which are carried out using patient-derived cells. Future innovations are moving towards using allogeneic therapies, where the cells used for therapy are derived from a healthy donor. Such advances are paving the way towards the development of universal donor cells, which would turn cell therapies into off-the-shelf treatments, enhancing the scale and accessibility of the treatments.

Finally, cell therapy methods are likely to move from ex vivo approaches (where cells are isolated from the patient, reprogrammed, and delivered back into the patient), to in vivo approaches, where cell therapies are delivered directly to the recipient, for example, through the use of small molecules present in a reprogramming cocktail or direct gene editing. In vivo technologies would, therefore, be able to reprogram cells directly in living humans, expanding the scope of cell therapy in a clinical setting. Overall, future cell therapies will have the capacity to be more effective, safer, and widely accessible.

MC: What are the key challenges that currently exist when developing and testing cell therapies? How does Mogrify hope to overcome such challenges?JF: The biggest challenges in producing cell therapies surround the efficacy, safety profile, and scalability of clinical treatment regimes. To make treatments safer, delivered cells must bypass the host immune system. This can be achieved with autologous therapy, but comes at the cost of scale and efficiency, as the patients cells need to be extracted, cultured, and reprogrammed before treatment can be delivered. Genetic engineering technologies (such as CRISPR/Cas9) that can be employed to remove the antigenic potential of allogeneic cell therapies (e.g. CAR-T) can be used in conjunction with such treatments, but this brings an additional layer of complication.Another difficulty comes from the technical challenges associated with generating, culturing, and expanding the required cells. In theory, any cell type can be derived from pluripotent cells. However, determining precisely how to generate any cell from pluripotent cells is conceptually and practically complex. Each cell type would require a distinct combination of transcription factors (or small molecules) and optimized culture conditions to ensure robust conversion into the desired phenotype. These technical challenges are associated with slow progress and poor efficiency in deriving reliable therapeutic cells.

Mogrify aims to tackle these hurdles with solutions involving big data, computational predictions, and bioinformatics. Mogrifys proprietary algorithm uses next generation sequencing data to predict the combination of transcription factors necessary to reliably convert any cell type into another cell type. Mogrifys technology provides a framework for direct cell conversion, and can also identify the best culture conditions to ensure that the cell populations remain stable and viable. This greatly improves cell therapy efficiency, as mature cells are created without the often arduous and imprecise process of differentiating cells from pluripotency.

Mogrifys technology is also compatible with in vivo cell therapies, as it can identify a combination of small molecules that will drive the necessary transcriptional networks to create the cells of choice. Therefore, Mogrifys technology can also be applied to overcome safety issues associated with allogeneic ex vivo approaches, and has the potential to greatly enhance the scale at which cell therapies can be delivered.MC: Are you able to tell us more about the latest developments in Mogrify's pipeline?JF: Currently, Mogrify is focused on applying the platform to musculoskeletal disorders, cancer immunotherapy, and auto-immune, ocular and respiratory diseases. Specifically, Mogrify is committed to identifying opportunities in regenerative medicine contexts, where direct cell conversion could have strong therapeutic potential.The current lead musculoskeletal program is in the development of chondrocytes for the treatment of cartilage defects and osteoarthritis. Mogrifys platform identified a cocktail of small molecules that successfully drives the conversion of fibroblast cells to chondrocytes, which has been proven to form functional hyaline cartilage in vitro. This can even be performed using an allogeneic approach without the need for gene editing (as the cartilage is immunopriviliged). Thus, it represents an opportunity for an off-the-shelf therapy that could be a relatively inexpensive and accessible treatment. At present, this treatment is in pre-clinical stages, and has a powerful potential for success in regenerative cartilage therapy. Similarly, an in vivo method of transdifferentiating osteoarthritic chondrocytes to healthy cells is being investigated in ongoing studies using a cocktail of small molecules.

Joe Foster, COO, Mogrify was speaking to Molly Campbell, Science Writer, Technology Networks.

Read more:
Leading the Movement Towards Direct Cell Conversion: An Interview With Mogrify - Technology Networks

SALT LAKE CITY, April 13, 2020 (GLOBE NEWSWIRE) -- Predictive Biology, a wholly owned subsidiary of Predictive Technology Group (OTC PINK: PRED) (Predictive or The Company), announced that on April 9th it submitted an Emergency Use Authorization (EUA) application with the U.S. Food and Drug Administration (FDA) for the immediate use of mesenchymal stem cells (MSCs) derived from umbilical cord tissue for the treatment of Acute Respiratory Distress Syndrome (ARDS), secondary to SARS-CoV-2, coronavirus disease 2019 (COVID-19).

The pandemic caused by COVID-19 has shown to develop into severe ARDS in 30% of hospitalized patients with a 22%-62% mortality rate (Murthy et al., 2020) for those requiring hospitalization in an intensive care unit. Currently, there is no confirmed treatment that can demonstrate safety or efficacy for the treatment of COVID-19.

Coronavirus can be deadly, in large part because the virus can cause cytokine storms in which the patients own immune system triggers a runaway response causing more damage to the patient, than to the virus it's trying to eliminate, said John Sorrentino, Chairman of Predictive Technology Group. Respiratory distress kills hundreds of thousands of people each year worldwide. There is clinical data from early clinical trials that seem to indicate that the avoidance of the cytokine storm utilizing MSCs may be a critical component for the treatment of COVID-19 infected patients.

A recent review article published in Pain Physician, concluded that, The limited but emerging evidence regarding UC MSC [umbilical cord mesenchymal stem cells] in managing COVID-19 suggests that it might be considered for compassionate use in critically ill patients to reduce morbidity and mortality in the United States.

The proposed IND clinical trial will utilize Predictives proprietary core technology of naturally occurring MSCs derived from umbilical cord tissue (UC-MSCs) to assess the efficacy as an add-on therapy to standard treatment of patients with severe Acute Respiratory Distress Syndrome (ARDS) secondary to COVID-19.

Predictives UC MSC product, CoreCyte, [currently regulated by the FDA as a tissue-based product under 21 CFR 1271.3(d)(1) and Section 361 of the Public Health Service Act] has already beenused as an allograft in over50,000 patients. Physicians have reported to Predictive that over 1,100 patients have been treated with CoreCyte via intravenous administration. No serious adverse events have been reported with CoreCyte regardless of the route of administration. If Predictives EUA request is approved, CoreCyte would be available immediately to critically ill patients with ARDS due to COVID-19 infections.

About Predictive Technology Group, Inc.

Predictive Technology Group aims to revolutionize and personalize precision patient care. The Companys entities harness predictive gene-based analytics to develop genetic and molecular diagnostic tests and companion therapeutics in order to support a patient from diagnosis through treatment.

Dedicated to identifying the barriers that impact lifelong health through our genetic library, genomic mapping and individualized diagnostics, Predictives tests and products empower clinicians to provide their patients with the highest level of care. For more information, visit http://www.predtechgroup.com

About Predictive Biotech, Inc.

Predictive Biotech is a leader in regenerative medicine, its products are derived from tissue sources rich in properties that support the bodys natural ability to heal itself. All products are safely, ethically and minimally processed to deliver allografts that preserve the naturally occurring characteristics and factors of the donor tissue. Predictives signature products are uniquely born from the Whartons jelly layer of the umbilical cord and amniotic fluid and tissue.

With over 100,000 units delivered, product safety and consistency has been realized by thousands of practices throughout the United States. A national network of clinics, health systems, researchers and physicians leverage Predictives four proprietary products: AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte.

Forward-Looking Statements:

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for human cell and tissue products and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment, and other risks The Company may identify from time to time in the future. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect The Company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect The Company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by The Company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts:

Predictive BiotechInfo@predictivebiotech.com888-407-9761

Investor ContactJeremy FefferLifeSci Advisorsjeremy@lifesciadvisors.com212-915-2568

Excerpt from:
Predictive Submits Emergency Use Authorization Application for Treatment of Acute Respiratory Distress Syndrome Secondary to COVID -19 with Umbilical...

You should read the following discussion together with our consolidatedfinancial statements and the related notes included elsewhere in this report.This discussion contains forward-looking statements, which involve risks anduncertainties. Our actual results may differ materially from those we currentlyanticipate as a result of many factors, including the factors we describe under"Risk Factors" and elsewhere in this report.

Some of the information in this section contains forward-looking statements thatinvolve substantial risks and uncertainties. You can identify these statementsby forward-looking words such as "may," "will," "expect," "anticipate,""believe," "estimate" and "continue," or similar words. You should readstatements that contain these words carefully because they:

discuss our future expectations;

contain projections of our future results of operations or of our financial

state other "forward-looking" information.

We believe it is important to communicate our expectations. However, there maybe events in the future that we are not able to accurately predict or over whichwe have no control. Our actual results and the timing of certain events coulddiffer materially from those anticipated in these forward-looking statements asa result of certain factors, including those set forth under "Risk Factors,""Business" and elsewhere in this report.

Unless stated otherwise, the words "we," "us," "our," the "Company" or "BiotechProducts Services and Research," "Organicell" in this section collectively referto Biotech Products Services and Research, Inc., a Nevada corporation, and itssubsidiaries.

We are engaged in the health care industry, principally focusing on supplyingproducts and services related to the growing field of regenerative anti-agingmedicine ("RAAM"). Our goal is to supply newly designed advanced biologicallyprocessed cellular and tissue-based products developed from internally-basedresearch and development activities and/or from other state-of-the-artRAAM-related products developed by third parties under exclusive and/orfavorable supply arrangements and to provide other related services used in thegrowing health care field of regenerative medicine ("RAAM Products"). We intendto distribute the RAAM Products and market RAAM-related services to the healthcare industry and a referral network of doctors and clinics (collectively, the"Providers").

From November 2016 to February 2018, we began operating our own laboratoryfacilities to process and distribute RAAM Products developed through tradesecrets acquired in connection with the employment of newly hired executivesduring November 2016 and March 2017. During this time, we also implemented anin-house sales force and made arrangements with newly identified independentdistributors to sell our RAAM Products. During February 2018, we sold ortransferred our laboratory facilities and all related assets ("Sale"), includingintellectual property rights, to Vera Acquisition LLC, a Utah limited liabilitycompany ("Vera"). The Company's decision to sell the assets comprising themanufacturing operations was made mostly to mitigate the substantial ongoingoperating risks associated with the operations of the manufacturing facility,including (a) lack of adequate working capital to pay wages to key executivesand to hire additional sales and manufacturing personnel and other criticallyneeded staff and to make required payments to vendors, (b) existing and newlyissued FDA guidelines released in November 2017 governing our manufacturingoperations that were projected to require significant additional capitalresources to be deployed to satisfactorily meet regulatory requirements withinspecified deadlines.

Since the Sale was completed, including the departure of several key executives,the Company had been unsuccessful in generating sufficient revenues and as aresult continued to have a lack of working capital to meet current operatingcosts, hiring of additional sales personnel, pay past due accounts payableobligations to its vendors, pay past due and/or current salaries to itsremaining management or fund potential growth opportunities.

On April 23, 2018, the Company and Management and Business Associates, LLC, aFlorida limited liability company ("MBA"), executed a Plan and Agreement ofReorganization ("Reorganization") whereby the Company agreed to issue to MBA anaggregate of 222,425,073 shares of its common stock of the Company, representingat the time a 51% of the outstanding shares of common stock of the Company onfully-diluted basis, for $0.001 per share (or an aggregate of $222,425), inconsideration for MBA's founder and Chief Executive Officer, Mr. ManuelIglesias' agreement to serve as the Company's Chief Executive Officer and amember of the Board of the Company. The Reorganization was effective as of April13, 2018 ("Effective Date").

Prior to the execution and effectiveness of the Reorganization, Mr. Iglesiasmoved from his position as Chief Executive Officer to a position as Co-Chairmanof the Board of Hygea Holdings Corp., a Florida corporation ("Hygea"), adiversified healthcare holding company that owns physician practices, ancillaryservices companies (e.g., pharmacies, therapies and diagnostic facilities),independent physician associations ("IPAs"), and other medical service entitiesthat provide seamless care to commercial, Medicare and Medicaid patients. As thenewly appointed Chief Executive Officer of the Company, Mr. Iglesias intended tobring his extensive industry experience and relationships to attract capital andindustry leaders to the Company as the Company sought to stabilize, expand andgrow the business into becoming a leading supplier of services, products andtherapies for the regenerative health care sector, including expansion into therapidly growing wellness sector, and to pursue clinical studies andcertifications for specific disease states using the expedited United StatesFood and Drug Administration ("FDA") program for regulatory approval forregenerative medicine advance therapies ("RMAT"). As part of the Company'sefforts to raise capital, the Company initiated and/or completed severalimportant corporate governance changes to simplify the Company's capitalstructure and to attract investment capital including:

1. On May 21, 2018, the Company filed a Certificate of Amendment with the

2. On May 21, 2018, the Company filed a Certificate of Amendment with the

Secretary of State of Nevada to effectuate a reverse stock split of one (1)

new share for each seventeen (17) shares issued and outstanding as of the

record date of May 21, 2018, with resulting fractional shares being rounded up

to the nearest whole number, and a reduction in the authorized shares from 750

million to 250 million (the "Reverse Split"). On June 18, the Company filed a

Certificate of Correction with the Secretary of State of Nevada to reverse the

amendments related to the Reverse Split, and will only file a new Certificate

of Amendment with the Secretary of State of Nevada to effectuate the Reverse

Split if the Reverse Split has been effectuated in the marketplace by FINRA.

The Company believes that a Reverse Split would bring value to the issued and

outstanding shares of the Company by limiting dilution of operating results by

an excessive number of shares overhanging the market. As discussed below, the

Reverse Split has not been effectuated in the marketplace by FINRA.

3. On June 14, 2018, the Company filed a Certificate of Withdrawal with the

Secretary of State of Nevada thereby withdrawing and terminating all

previously issued designations of the Company's Series A Preferred Stock and

Series B Preferred Stock. The Company cancelled the Company's authorized and

outstanding Series A Preferred Stock and Series B Preferred Stock in order to

provide investors with greater confidence in the value to the issued and

outstanding shares of the Company by limiting dilution of operating results

and limitation on preferences granted to other investors.

4. The Company reached agreement with its key executive management in connection

5. The Company reconstituted its Board of Directors and appointed an independent

outside director. Since the Reorganization, the Company has added additional

members to its Board of Directors.

On June 1, 2018, the Company submitted an Issuer Company-Related NotificationForm ("June 1 Notification Form") with the Financial Industry Regulatory Agency("FINRA") pursuant to Rule 10b-17 of the Securities Exchange Act of 1934, asamended (the "Exchange Act"), regarding the Name Change and Reverse Split.However, due to the Company's failing to have the required Exchange Act reportsfiled with the SEC at the time of the filing, FINRA did not announce oreffectuate the Name Change or Reverse Split in the marketplace. If the Companyintends to proceed with the Name Change and/or Reverse Split, the Company willbe required to submit a new Issuer Company-Related Notification Form forapproval upon the Company becoming current in its Exchange Act filings.

During February 2019, the Company began arranging to once again operate a newlaboratory facility in Miami, Florida for the purpose of performing research anddevelopment, production and manufacturing of anti-aging and cellular therapyproducts. This new laboratory facility became operational in May 2019 and duringthe same period, the Company began producing and distributing the products thatare being sold and distributed to its customers. The Company believes that thisstrategy will provide the Company with competitive advantages and greaterassurances that it can continue to comply with expected future FDA regulations.

In connection with the Company's ongoing research and development efforts andthe Company's efforts to meet compliance with current and anticipated UnitedStates Food and Drug Administration ("FDA") regulations expected to be enforcedbeginning in November 2020 pertaining to marketing traditional biologics andhuman cells, tissues and cellular and tissue based products that fall underSection 351 of the Public Health Services Act ("HCT/Ps"), the Company appliedfor and on July 14, 2019, the Company received Institutional Review Board("IRB") approval to proceed with two pilot studies in connection with theCompany's efforts to obtain Investigation New Drug ("IND") approval from the FDAand commence clinical trials in connection with the use of the Company'sproducts and related treatment protocols for specific indications. The Companyis aggressively pursuing efforts to obtain the aforementioned IND approvals andcommence and complete those clinical studies as well as obtaining approval tocommence additional studies for other specific indications it has identifiedthat the use of its products will provide more favorable and desired healthrelated benefits for patients seeking alternative treatment options than arecurrently available. The ability of the Company to succeed in these efforts issubject to the Company having sufficient available working capital to fund thesubstantial costs, which the Company currently does not have, and ultimately theapproval from the FDA.

On September 24, 2019, due to the Company's limited success since theReorganization in stabilizing revenues and the growing urgency for the Companyto remain compliant and meet the anticipated new and more stringent regulatorydeadlines to be imposed by the FDA in connection with the Company's products andoperations that were previously announced to go into effect in November 2020,the Board determined that it would require the services of a full-time CEO withthe requisite expertise and experience to lead the Company as it (a) movesforward with its strategy to expand its research and development efforts andsubmit IND applications for FDA approval to commence clinical trials for itsproducts to assure that the Company, its operations and its products remaincompliant with FDA regulations and (b) implements additional strategies tominimize the potential impact in the future on sales of its products as a resultof future changes in FDA regulations and/or restrictions associated withclinical trials that are utilizing the products that are currently being sold bythe Company. Accordingly, the Board voted to remove Manuel Iglesias from hisposition as CEO of the Company, although he remains as non-executive Chairman ofthe Board and a director and has been offered an alternative senior managementposition with the Company. The Board also authorized management to proceed witha search for a full-time CEO and management has identified and has beguninterviewing potential candidates.

As of October 31, 2017, Mint Organics had not been successful in obtaining aFlorida license allowing Mint Organics or Mint Organics Florida to operate abusiness to dispense medical cannabis. In addition, Mint Organics had exhaustedall of its working capital and Organicell was unable to identify additionalsources of working capital.

On April 6, 2018, Mr. Taddeo resigned as a member of the Board of Directors ofthe Company and as the Chief Executive Officer and member of the Board ofDirectors of Mint Organics and Mint Organics Florida. Mr. Taddeo's resignationwas due to his decision to pursue other personal objectives, particularly inlight of the ongoing lack of adequate working capital at Mint Organics todemonstrate the ability to fund a reasonable level of future cash compensationto Mr. Taddeo and the additional capital required to sustain future effortsrequired to successfully pursue obtaining a license to operate cannabisdispensaries.

The Company had since decided that it would not pursue any additional efforts toobtain licenses to operate MMTC's. During May 2019, the Company agreed toexchange the equity held by the remaining minority interest holders of MintOrganics and Mint Organics Florida and to convert all of the outstanding debt ofMint Organics into shares of common stock of the Company.

For the years ended October 31, 2018 and 2017, our RAAM-related operations werebeing conducted through the following wholly-owned subsidiaries*:

Anu Life Sciences, Inc., a Florida corporation formed with a business purpose

General Surgical Florida, Inc., a Florida corporation with a business purpose

of selling and distributing regenerative biologic therapies based on amnion

placental tissue derived products to doctors and hospitals.

Beyond Cells Corp., a Florida corporation formed with a business purpose to

provide consumers with education regarding the field of regenerative and

anti-aging and medicine and providing access to a specialized physician network

* As described above, the manufacturing operations of ANU were sold duringFebruary 2018, and the Company subsequently relied on supply arrangements withthird-party manufacturers or indirectly from distributors of third-partymanufacturers for the supply of RAAM products that were sold to Providers duringthe period February 6, 2018 through October 31, 2018.

Our MMTC exploratory activities were conducted through the below listedsubsidiaries. Effective April 6, 2018, Mr. Taddeo resigned as CEO of our MMTCsubsidiaries. The Company had since decided that it would not pursue anyadditional efforts to obtain licenses to operate MMTC's. During May 2019, theCompany agreed to exchange the equity held by the remaining minority interestholders of Mint Organics and Mint Organics Florida and to convert all of theoutstanding debt of Mint Organics into shares of common stock of the Company**.As a result, Mint Organics, Inc. and Mint Organics Florida, Inc. are presentlyinactive and have no assets:

Mint Organics, Inc., a Florida corporation with a business purpose of operating

Medical Marijuana Treatment Centers for defined MMTC licensed activities; and

Mint Organics Florida, Inc., a Florida corporation and subsidiary of Mint

Organics with a business purpose of operating Medical Marijuana Treatment

Centers for defined MMTC licensed activities within Florida.

** Mint Organics and Mint Organics Florida had previously issued minoritynon-voting equity interests which as of May 2019 are all owned by the Company.

We also have two other wholly-owned subsidiaries that are inactive:

Ethan New York, Inc., a New York corporation formed with a business purpose of

selling clothing and accessories through a retail store in New York City

("Ethan NY") and for which operations ended in June 2016; and

BD Source and Distribution, Corp., a Florida corporation ("BD Source") formed

Current and Future Operations:

Our current strategy is to achieve the following goals and milestones:

Develop and expand operations to provide for growth of our revenues for thesales and distribution of RAAM related products;

o Increase revenues for RAAM related products;

Hiring of additional in-house sales personnel

Selectively engaging independent distributors

Marketing private label products to distributors

Increasing market recognition for our Organicell brand from:

marketing and participating in industry trade shows

o Expand our sales market outside of the United States

o Increase the number of RAAM product offerings for various modalities using

proprietary processing, formulas and administration techniques

o Extending our referral network of Providers based on:

Superior product offerings

Demonstrating a realistic and executable regulatory roadmap to assure Company

and product compliance with current and anticipated FDA regulations

Developing and providing educational support to Providers regarding our

Execute on current strategy to assure the Company's ability to maintaincompliance with existing and the anticipated changes to FDA regulationsregarding the use and sale of our current products published in November 2017and expected to take effect by November 2020, as well as readiness to respond toongoing future changes to those regulations:

o Identify qualified candidates to fill the currently vacant CEO position that

have the requisite expertise and experience to lead the Company as it moves

forward with its strategy to enhance product research and development and

execute clinical trials of the Company's products, and

o Perform clinical based studies associated with the use of our products

(independently and/or in conjunction with Providers and/or Manufacturers) and

seek accelerated approval for each product application in accordance with the

21st Century Cures Act ("Cures Act") and/or through the granting of an

FDA-approved biologics application (BLA) to allow products to be lawfully

marketed and/or sold in the United States in accordance with newly established

FDA guidelines outlined in November 2017 expected to take effect by November

2020; and

o Continue to build out our lab facilities to meet expected production and

research requirements; and

o Engage high profile and industry recognized medical advisors and scientists to

More here:
ORGANICELL REGENERATIVE MEDICINE : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-K) -...

Aleksandra Seweryn,1 Ariadna Pielok,2 Krystyna Lawniczak-Jablonska,1 Rafal Pietruszka,1 Klaudia Marcinkowska,2 Mateusz Sikora,2 Bartlomiej S Witkowski,1 Marek Godlewski,1 Krzysztof Marycz,2,3 Agnieszka Smieszek2

1Institute of Physics, Polish Academy of Sciences, Warsaw PL-02668, Poland; 2Wroclaw University of Environmental and Life Sciences, Department of Experimental Biology, Wroclaw PL-50375, Poland; 3Cardinal Stefan Wyszynski University, Collegium Medicum, Warsaw PL-01938, Poland

Correspondence: Aleksandra SewerynPolish Academy of Sciences, Aleja Lotnikow 32/46, Warsaw PL-02668, PolandTel +48 22 116 33 99Fax +48 22 843 09 26Email aseweryn@ifpan.edu.plAgnieszka SmieszekWroclaw University of Environmental and Life Sciences, Norwida St. 27 B, Wroclaw PL-50-375, PolandTel +48 71 320 5229Fax +48 22 843 09 26Email agnieszka.smieszek@upwr.edu.pl

Introduction: The development of the field of biomaterials engineering is rapid. Various bioactive coatings are created to improve the biocompatibility of substrates used for bone regeneration, which includes formulation of thin zirconia coatings with pro-osteogenic properties. The aim of this study was to assess the biological properties of ZrO2 thin films grown by Atomic Layer Deposition (ALD) technology (ZrO2ALD).Methodology: The cytocompatibility of the obtained layers was analysed using the mice pre-osteoblastic cell line (MC3T3) characterized by decreased expression of microRNA 21-5p (miR-21-5p) in order to evaluate the potential pro-osteogenic properties of the coatings. The in vitro experiments were designed to determine the effect of ZrO2ALD coatings on cell morphology (confocal microscope), proliferative activity (cell cycle analysis) and metabolism, reflected by mitochondrial membrane potential (cytometric-based measurement). Additionally, the influence of layers on the expression of genes associated with cell survival and osteogenesis was studied using RT-qPCR. The following genes were investigated: B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), p53 and p21, as well as osteogenic markers, i.e. collagen type 1 (Coll-1), osteopontin (Opn), osteocalcin (Ocl) and runt-related transcription factor 2 (Runx-2). The levels of microRNA (miRNA/miR) involved in the regulation of osteogenic genes were determined, including miR-7, miR-21, miR-124 and miR-223.Results: The analysis revealed that the obtained coatings are cytocompatible and may increase the metabolism of pre-osteoblast, which was correlated with increased mitochondrial membrane potential and extensive development of the mitochondrial network. The obtained coatings affected the viability and proliferative status of cells, reducing the population of actively dividing cells. However, in cultures propagated on ZrO2ALD coatings, the up-regulation of genes essential for bone metabolism was noted.Discussion: The data obtained indicate that ZrO2 coatings created using the ALD method may have pro-osteogenic properties and may improve the metabolism of bone precursor cells. Given the above, further development of ZrO2ALD layers is essential in terms of their potential clinical application in bone regenerative medicine.

Keywords: ALD, zirconia-based coatings, pro-osteogenic properties, cytocompatibility, osteoblasts precursors

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

See the original post here:
Zirconium Oxide Thin Films Obtained by Atomic Layer Deposition Technol | IJN - Dove Medical Press

Faculty members Lohitash Karumbaiah and Donnie Longenecker have been selected as the University of Georgias Innovation Fellows for spring 2020 and will spend the semester learning how to successfully translate their research into marketable products.

Karumbaiah is an associate professor of regenerative medicine in the department of animal and dairy science and the Regenerative Bioscience Center. He conducts preclinical research on invasive tumors and traumatic brain injuries. He previously underwent training through the UGA I-Corps Accelerator program, aiming to create solutions for these brain-related pathologies.

Longenecker, a senior lecturer in the College of Environment and Design, studies performance improvements in the landscape architecture industry and the impact of continuing education on that performance. As an Innovation Fellow, he will convert this research into educational products determined to be of value both by industry regulators and landscape architects themselves. In partnership with the CED, Longeneckers goal is to develop and provide new educational programs to the landscape architecture industry.

Launched last fall as part of UGAs Innovation District initiative, the Innovations Fellows program aims to encourage faculty and staff to capitalize on the resources available through UGAs research commercialization office, Innovation Gateway, to pursue their interest in commercialization and product development.

I-Corps introduced me to the wealth of resources and expertise available to identify unmet needs and develop products and technologies to bridge therapeutic gaps, said Karumbaiah, whose research is currently funded by the National Institutes of Health and the National Science Foundations Engineering Research Center for Cell Manufacturing Therapies. I applied to the UGA Innovation Fellows Program on the back of this experience to continue to develop the knowledge base required to translate academic research innovations into clinically viable solutions.

Our outreach should improve when you consider that UGA is one of the largest landscape architecture programs in the U.S., and it has recently been ranked as the No. 1 place to hire landscape architecture grads by Design Intelligence Magazine, said Longenecker. Im hoping that through the process of customer discovery, developing a specific value proposition and understanding the logistics of delivery and organization, I can make our outreach efforts much more effective.

In addition to funding of up to $10,000, each Fellow will dive into a weeklong crash course on Gateways innovation curriculum, which will be followed by an eight-hour-per-week commitment to complete the program.

Our hope is to not only educate our faculty and staff on the value of the commercializing process, but also on the potential their research has for the local and global markets, said Ian Biggs, director of the startups program in Innovation Gateway. The ultimate goal is making our community and the world a safer, smarter place to live, and through the Innovation District initiative and our Innovation Fellows, UGAs one step closer to meeting that goal.

See original here:
Two faculty members named Innovation Fellows - University of Georgia